🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

In honor of International Day of Women and Girls in Science earlier this week, we’re spotlighting Ali Johnson, our Staff Scientist & Lab Manager at the Seattle Translational Research Lab! With a deep passion for molecular biology and disease mechanisms, Ali has dedicated her

Renibus Therapeutics is looking forward to participating in the 24th Annual Needham Virtual Healthcare Conference, taking place April 7-10, 2025. Company management team will participate in virtual one-on-one meetings during the conference. Learn more here: lnkd.in/gbrqpZdA

Meet Stewart A. Turner, PhD, our Vice President of Medical Affairs at Renibus Therapeutics! Originally from Liverpool, UK, Stewart discovered his passion for life sciences while completing his PhD at the University of London. Today, he’s focused on building a high-impact Medical Affairs

#BREAKING: Today, we are thrilled to announce the completion of enrollment in PROTECT, a pivotal Phase 3 trial evaluating the effect of RBT-1 on reducing the risk of post-operative complications in patients undergoing cardiac surgery. Learn more here: prnewswire.com/news-releases/…

Despite an improvement in surgical and anesthesia techniques that has resulted in a significant decrease in mortality, postoperative complications play a major role in affecting morbidity, mortality, length of hospital stay and patients' quality of life. Innovation is desperately

PROTECT, a pivotal Phase 3 trial evaluating the effect of RBT-1 on reducing the risk of post-operative complications in patients undergoing cardiac surgery, enrolled 423 patients across 40 trial sites in the United States and Canada. Topline results from the study are anticipated

This Sunday, April 27th, Frans van Wagenberg, MD, Cardiothoracic Surgeon from Huntsville Heart Center, will give a poster presentation at the highly anticipated Society of Cardiovascular Anesthesiologists (SCA) 47th Annual Meeting in Montreal, Canada. Learn more here:

Renibus Therapeutics Inc is proud to be attending the Third Annual ERAS All Sponsor Retreat as a platinum corporate sponsor on May 1st in Seattle. The Society for Enhanced Recovery After Cardiac Surgery (ERAS® Cardiac) is dedicated to optimizing perioperative care for cardiac

The Renibus Therapeutics team is in Montreal for the #ISPOR Annual meeting! We're proud to contribute to the dialogue on how novel therapies like RBT-1 have the potential to reduce the risk of post-operative complications in cardiac surgery patients and help drive cost-effective care.

#BREAKING: Today, we are thrilled to announce the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to veverimer for the treatment of anti-glomerular basement membrane disease (anti-GBM), an ultra-rare life-threatening condition characterized by acute

In cases you missed it, earlier today, we announced the FDA granted Orphan Drug Designation to veverimer for the treatment of Anti-glomerular basement membrane disease (anti-GBM). Anti-GBM is an ultra-rare, life-threatening autoimmune condition that, like other glomerular and

The Orphan Drug Designation (ODD) program is designed to encourage the development of treatments for diseases affecting fewer than 200,000 people in the U.S. That’s why we’re proud to share that the FDA has granted Orphan Drug Designation to veverimer for the treatment of

Attending the APACVS 44th Annual Meeting in Portland? Come visit our Medical Affairs team at booth #302 to learn more about PROTECT™, our pivotal Phase 3 trial of RBT-1, which is recently fully enrolled. The study is evaluating RBT-1’s potential to reduce post-operative

The Renibus Therapeutics team is hitting the road and heading to Dana Point, California, to attend the Western Thoracic Surgical Association 51st Annual Meeting. We’ll be there from June 25th to 28th and would love to connect with you! #CardioRenal #CTsurgery #Cardio #CriticalCare

Thank you to the National Infusion Center Association (NICA) for a memorable NICA 2025 Annual Conference! We were proud to join peers advancing innovation in infusion care and contribute to the dialogue on how novel, infusion-delivered therapies like RBT-1 have the potential to

Wishing you a joyful and safe 4th of July weekend from all of us at Renibus Therapeutics! 🇺🇸 Let’s celebrate our freedoms and continue to work together for a healthier tomorrow. #HappyFourth #LetFreedomRing

We’re headed to the Florida Society of Thoracic and Cardiovascular Surgeons Annual Scientific Meeting later this week! The Renibus Therapeutics team will be in town July 10 to 13 and we would love to connect with you! #CTsurgery #CardioThoracicSurgery #Cardio #CriticalCare #FSTCS2025

Thank you to the Florida Society of Thoracic and Cardiovascular Surgeons for a memorable meeting! Our team enjoyed connecting with meeting attendees and sharing how RBT-1 has potential to reduce post-operative complications in cardiothoracic surgery patients and supports more